Pharmaceutical Commercial Consultantt Specializing in Disease Strategies

Technical Consultant #1928


Expertise

  • Pharmaceutical marketing, strategy, and product commercialization leader with over 15 years of experience in pharmaceuticals small and large molecules commercial representation on development teams.
  • Commercial aspects of product development from preclinical through post-launch phases and in identifying key unmet needs and defining market opportunities.
  • Strategic and commercial analyses with actionable recommendations for products, business development, markets, research and development, and portfolios.
  • Proven ability to optimize a product's value and sustainable competitive advantage by understanding and articulating the needs of caregivers, patients, prescribers, and payers by understanding the competitive environment including future competitive compounds and technologies.
  • Product and portfolio forecasting and valuations - brand creation and launch.
  • Asset and disease assessments and disease strategies.

Experience

Undisclosed Company, Managing Partner, 2012 - Present

  • Pharmaceutical and biotechnology industry lead: Develops, and provides commercial and strategic insight support for companies, institutions, and individuals.
  • Client-facing roles include business prospecting and development, account services, and project interactions.
  • Recent projects include developing global brand strategies and tactics for vaccines and women's infertility.
  • Developed short and long-term brand and vaccine portfolio strategies; key issues were related to public policy strategies in the BRIC markets.
  • Developed global commercialization strategy for a leading vaccine with emphasis on novel customer segments.
  • Completed packaging strategy for a new infertility product for a top 15 global pharmaceutical company.

Pfizer, Collegeville, PA, 2009 - 2010

Director, Early Commercial Development, Women's Health and Urology, Primary Care

  • Provided commercial guidance and strategic support for development assets.
  • Provided commercial assessments of business development opportunities and partnered with disease area leadership on development of strategic initiatives related to women's health, genitourinary, endometriosis, IC, urinary incontinence, sexual dysfunction, testosterone deficiency, musculoskeletal, osteoporosis, and osteoarthritis.
  • Commercial assessments and recommendations saving over $500 million in investments for in-licensing and acquisition targets.
  • Selected to lead high-priority reassessment process including: new positioning; payer, prescriber, and patient market research; and a forecast model; findings and recommendation reversed termination of a Phase II asset for OA pain; development resumed based on new forecasted peak-year sales of over $1 billion.
  • Led cross-functional teams in crafting innovative disease area strategies and new product concepts for: Female sexual dysfunction, endometriosis, menopausal symptoms (VMS), osteoporosis, aesthetics, overactive bladder/ incontinence, interstitial cystitis, nocturia, and chronic prostatitis, used in guiding new drug development, licensing activities, and short and long-term strategy development.
  • Delivered commercial analyses for more than ten conditions, a device, and other in-licensing opportunities.
  • Collaborated with Business Development and other operational areas on the evaluation of external licensing candidates to complement internal assets to optimize the pipeline; set up, defined, and used market research, customer insight, and forecast modeling to evaluate business and value proposition of assets.

Wyeth, Collegeville, PA, 2002 - 2009

Senior Director, Neuroscience, New Business, 2008 - 2009

  • Commercial representative on six cross-functional development teams.
  • Developed and ensured commercial strategies and clinical programs for development compounds in nociceptive and neuropathic pain control (lead indications OA, fibromyalgia), ischemic stroke, and multiple sclerosis (MS) were implemented to ensure products would provide innovative and medically valuable differentiation; included definition of health outcomes and pharmacoeconomic attributes that supported commercial viability of products in development.
  • Developed target product profiles for preclinical compounds in pain control to ensure pipeline would provide candidates offering innovative and medically valuable differentiation.
  • Led multidisciplinary teams in the development of disease-area strategies and assessments for pain, ischemic stroke, multiple sclerosis, Parkinson's disease and other conditions that provided objectives, strategies, and tactics for establishing and achieving objectives of the business unit; ratified by senior leaders and implemented by the business unit.
  • Collaborated with Business Development and other operational areas on the evaluation of external licensing candidates to complement internal assets to optimize the pipeline.

Senior Director, Women's Health Care, New Products, 2005 - 2008

  • Led project that established the research and development, and commercialization strategies for the Women's Health Care franchise in collaboration with discovery.
  • Provided the efficacy, safety, clinical attributes of an ideal product for target indications, the potential daily price in key markets, and the factors driving value.
  • Led cross-functional team on assessing the market potential, target product profile, key claims, optimal proof of concept clinical trial design, pricing, forecast, and regulatory issues for sarcopenia, a new area for company; timeline required fast, complex market research, and extensive internal and external collaboration.
  • Represented new products on cross-functional teams.
  • Developed company wide initiatives including: new drug-development methods; implementation, and support of a global product launch process; positioning and value proposition processes; a standardized target product profile.
  • Commercial lead on cross-functional development teams.
  • Ensured commercial strategies and clinical programs for development projects (discovery through Phase III) related to reproduction, endometriosis, IC, uterine fibroids; pain relief of neuropathic conditions, and sarcopenia.
  • Strategies implemented to ensure products would provide innovative and medically valuable differentiation when commercialized; included definition of health outcomes and pharmacoeconomic attributes that supported commercial viability of products in development.
  • Collaborated with discovery, and developed the Women's Health Musculoskeletal & Bone Opportunity Assessment used in guiding new drug development, licensing activities, and short and long-term strategies for the business unit.
  • Developed commercial analyses, strategies, and programs for conditions and for in-licensing opportunities related to Women's Health.
  • Collaborated with Business Development and other operational areas on the evaluation of external licensing candidates to complement internal assets to optimize the pipeline.
  • Received "Development Track Award", from Wyeth.

Director, Contraception, New Products, Women's Health Care, 2002 - 2004

  • Collaborated with cross-functional senior leaders in developing the first 10-year strategic plan for Women's Health Care; recognized for leading cross-functional assessment for over 80 conditions for Women's Health investment that drove the Business and Discovery Units' strategic and tactical plans.
  • Commercial lead on cross-functional development teams, (oral products and redevelopment).
  • Developed market research plan, market forecast, and recommendation for investment in male contraception discovery efforts and commercialization strategy.
  • Collaborated with Business Development and other operational areas on the evaluation of external licensing candidates to complement internal assets to optimize the pipeline.

Wyeth International, 1992 - 1997

Director, Contraception, International Marketing, 1992 - 2001

  • Directed all commercial planning and activities, and developed and implemented strategies for both in-line and development assets for $800 million Wyeth contraceptive franchise
  • Developed and implemented commercial prelaunch and launch strategies, branding, pricing, messaging, and related tactical programs for Minesse, a paradigm shifting contraceptive, and for the Loette acne indication

Gold Award: Minesse MRP.

  • Providing rapid response, performance in gaining European approval, and regulatory labeling.
  • Franchise lead on Gestodene Steering Committee that governed co-marketing of products with Schering AG and other strategic partnership issues.
  • Reviewed, revised, and approved ex-U.S. affiliate (45 markets) marketing and launch plans of all oral contraceptives and Norplant (implantable device) to ensure adherence to the corporate product positioning and global strategy while optimizing local success.
  • Worked with Japan affiliate leadership and Asia-Pacific Group Operations in development of the marketing strategy and launch of Tridol, the leading product in the newly-developed Japan oral contraceptive market.
  • Received "Commercial Support Award" for Asia Pacific Operations Group.
  • Collaborated on gaining agreement of the State Family Planning Committee (SFPC) leadership of the People's Republic of China to approve use of Minulet and to partner with Wyeth on population control programs.
  • Collaborated with SFPC leadership, regional management, KOLs, and local PRC Wyeth affiliate colleagues on launch, commercialization, and follow-on programs.
  • Collaborated with Business Development and other operational areas on the evaluation of external licensing candidates to complement internal assets to optimize the pipeline.

Associate Product Manager through Director, 1992 - 1997

  • Held various positions of increasing responsibility in new product development and ex-U.S. in-line marketing.
  • Assisted or fully responsible for development of marketing plans and tactics, KOLs, pricing, messaging, branding, pre-launch, launch, and post-launch strategy and support of ex-U.S. commercialization of Lodine SR (NSAID), Harmonet (OC), Effexor/Efexor (SNRI), and benzodiazepines.
  • Awarded "Gold Award of Excellence: "Global Packaging".

Honors & Publications

Academic and Professional Affiliations

  • Greater Philadelphia Senior Executive Group (GPSEG)
  • GPSEG Life Sciences' Pharmaceutical Working Group Chair

Awards

  • Several Awards from The Wharton School of Philadelphia, Philadelphia Marketing Association and Wyeth Pharmaceuticals in the areas of creation workshops, packaging and global positioning.

Education

  • B.A. Biology, La Salle University, Philadelphia, PA
Save Resume #1928
to Contact Form?

You must first click "Yes" to save this resume

Submit Request

You have no Saved Resumes

Add resumes within our various Ares of Expertise by clicking "Add Resume(s)" below.

Add Resume(s)